Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$1.94 USD
+0.02 (1.04%)
Updated Jun 4, 2024 03:59 PM ET
After-Market: $1.94 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Revelation Biosciences, Inc. [REVB]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Preclinical Evidence That IV Gemini Can Prevent Acute Kidney Injury
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Begins First Phase 1 for Gemini - Results Mid-2024, Funded Into 2025
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
3Q23: Preclinical Data For PHAD''s Gemini Formulation Support Phase 1 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Preclinical Data With Gemini Formulation Of PHAD Supports Phase 1 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
2Q23: Preclinical Clinical Data Coming In 2023 & 2024, Cash To Mid-2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
1Q23: Preclinical Clinical Data Coming In 2023 & 2024, Cash To Mid-2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
4Q22: Preclinical & Clinical Data Coming In 2023 & 2024, Cash To Mid-2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J